Algorae Pharmaceuticals Issues Cleansing Notice for Newly Issued Shares

Living Cell Technologies ( (AU:1AI) ) has provided an update.

Algorae Pharmaceuticals has issued new fully paid ordinary shares, as reflected in an Appendix 2A lodged on the ASX, and has confirmed that these securities were issued without the need for a prospectus or disclosure document under Part 6D.2 of the Corporations Act. The company also affirms it is up to date with its financial reporting and continuous disclosure obligations and states there is no excluded information that must be disclosed, effectively cleansing the newly issued shares for secondary trading and reinforcing regulatory compliance for investors.

This notice underscores Algorae’s adherence to key provisions of the Corporations Act, including chapters related to financial reporting and market disclosure, which is important for maintaining investor confidence and secondary market liquidity for its shares. By providing this cleansing notice, the company facilitates smoother trading of the new securities on the ASX and signals to stakeholders that there are no undisclosed material facts affecting the value of the issued shares.

The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.

More about Living Cell Technologies

Algorae Pharmaceuticals Limited is an Australian biotechnology company listed on the ASX, focused on developing pharmaceutical products and related technologies. The company operates within the life sciences sector and is subject to Australia’s Corporations Act and continuous disclosure obligations as a listed entity.

YTD Price Performance: 21.43%

Average Trading Volume: 1,504,027

Technical Sentiment Signal: Hold

Current Market Cap: A$29.19M

For an in-depth examination of 1AI stock, go to TipRanks’ Overview page.